Prospective multivariate analysis of donor monoethylglycine xylidide (MEGX) testing in liver transplantation. Transplantation Society of Michigan Scientific Studies Committee.

Measurement of the metabolism of lidocaine to MEGX by the hepatic cytochrome P450 system has been proposed as a means to assess liver function and metabolic activity of cadaveric organ donors. This prospective study of 102 potential liver donors from the State of Michigan sought to determine the role of MEGX determinations alone and in conjunction with traditional measures of donor acceptability. High MEGX values (> 80 microg/L) did not correlate with the acceptability of donor livers, and had no significant association with early posttransplant graft function, as determined by SGOT, SGPT, alkaline phosphatase, bilirubin, prothrombin time, or bile production. However, livers procured from donors with high MEGX values had improved actuarial graft survival when compared to low MEGX donors at 30 d (95% vs. 84%) and at 1 yr (68% vs. 43%) (p < 0.04). Multivariate analysis demonstrated a significant independent association of both shorter cold ischemic time and high MEGX value with improved graft survival (p < 0.002). We conclude that the MEGX test offers limited incremental value in predicting early function of donor livers when used in conjunction with traditional criteria of clinical evaluation, laboratory tests, and histology. However, knowledge of the results of MEGX determinations may be of value in predicting graft survival after liver transplantation.